3.7807.58% ( -0.310 )
Trading: Nov 16, 10:02:11 (EDT)Financials
Q3 FY2026 EarningsQ3 FY26 missed consensus estimates significantly across all profitability metrics, driven primarily by non-cash charges related to the Legacy Azora acquisition. Revenue remains at $0 in line with expectations for this clinical-stage biopharmaceutical entity. GAAP Net Loss of $64.6M was substantially wider than the $3.0M anticipated by analysts, largely due to a $57.1M fair value adjustment of milestone warrant rights. While the company maintains a $22.0M cash position, management issued a going concern warning, indicating current liquidity is insufficient to fund operations for the next twelve months.
Financial report interval: 2026.06.30 - 2026.09.30
Overview: Azora Therapeutics(AZR) the EBIT is -7.531 M (--%), Miss estimate;the EPS is -4.52 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B--
-0.00B--
-0.00B--%
EPSMiss expectations
-4.52--
-0.525--
-3.9950--%
Upcoming earnings report - FY2026 Q3 Earning Release
Available dateNov 18, 2026
Estimate Revenue0
Estimate EBIT-3.233 M
Estimate EPS-0.525
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly
